Efficacy of the association of a single dose of hepatitis B hyperimmune gammaglobulin and entecavir in the prophylaxis of hepatitis B after liver transplantation: Experience of a single center in Argentina;Eficacia de la asociación de una sola dosis de gamaglobulina hiperinmune anti-hepatitis B más entecavir en la profilaxis de la hepatitis B después del trasplante hepático: Experiencia de un centro en la Argentina

Acta Gastroenterologica Latinoamericana

Volumn 43, Issue 2, 2013, Pages 121-125

  Anders, María ^a   Orozco, Federico ^a   Goldaracena, Nicolás ^a   Quiñonez, Emilio ^a   McCormack, Lucas ^a   Mastai, Ricardo ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

Entecavir; Hepatitis B; Hepatitis B immunoglobulin (HBIg); Liver transplantation; Prophylaxis

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HYPERIMMUNE GLOBULIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; AGED; ANTIVIRAL AGENTS; ARGENTINA; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84878999170     PISSN: 03009033     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Instituto Nacional Coordinador Único de Ablación e Implante. http://www.incucai.gov.ar
2. Lee W. Hepatitis B virus infection. N Eng J Med 1997;337:1733-1745
3. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991;13:619-626
4. Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, Brechot C, Bismuth H. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991;337:813-815
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. New Eng J Med 1998;339:61-68
6. Bzowej N, Han S, Degertekin B, Keeffe EB, Emre S, Brown R, Reddy R, Lok AS. Liver transplantation outcomes among Caucasians, Asian Americans and African Americans with hepatitis B. Liver Transpl 2009;15:1010-1020
7. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation lamivudine Transplant Group. Hepatology 1999;29:1581-1586
8. Neff GW, O'Brien CB, Nery J, Shire N, Montalbano M, Ruiz P, Nery C, Sadfar K, De Medina M, Tzakis AG, Schiff ER, Madariaga J. Outcomes in liver transplant recipients with hepatitis B virus, resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004;10:1372-1378
9. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-1838
10. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, Shen CH, Luo Y, Xin TY, Wang SY, Qiu de K. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009;10:321-327
11. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514
12. Samuel D, Muller R, Alexander G. Liver transplantation in European patients with the hepatitis B surface antigen. N Eng J Med 1993;239:1842-1847
13. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998;28: 555-561
14. Chan HL, Chui AK, Lau WY, Chan FK, Hui AY, Rao AR, Wong J, Lai EC, Sung JJ. Outcome of lamivudine resistant hepatitis B virus mutant post liver transplantation on lamivudine inmunoprophylaxis. Clin Transplant 2004;18:295-300
15. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow up. Transplantation 2000;50:809-815
16. Terrault N, Roche B, Samuel D. Management of hepatitis B virus in the liver transplantation setting: an European and an America perspective. Liver Transpl 2005,11:716-732
17. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in supressing hepatitis B virus after liver transplantation. Gastroenterology 2011;141:1212-1219
18. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylatic therapy. Liver Transpl 2011;17:955-962.